Gilead Sciences, Inc. (GILD)
146.76
+0.64
(+0.44%)
USD |
NASDAQ |
Aug 24, 16:00
146.50
-0.26
(-0.18%)
After-Hours: 20:00
Gilead Sciences Net Income (Quarterly) : -10.50B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.50B |
| March 31, 2026 | 2.021B |
| December 31, 2025 | 2.183B |
| September 30, 2025 | 3.052B |
| June 30, 2025 | 1.96B |
| March 31, 2025 | 1.315B |
| December 31, 2024 | 1.783B |
| September 30, 2024 | 1.253B |
| June 30, 2024 | 1.614B |
| March 31, 2024 | -4.17B |
| December 31, 2023 | 1.417B |
| September 30, 2023 | 2.172B |
| June 30, 2023 | 1.039B |
| March 31, 2023 | 985.00M |
| December 31, 2022 | 1.633B |
| September 30, 2022 | 1.786B |
| June 30, 2022 | 1.135B |
| March 31, 2022 | 12.00M |
| December 31, 2021 | 376.00M |
| September 30, 2021 | 2.586B |
| June 30, 2021 | 1.517B |
| March 31, 2021 | 1.722B |
| December 31, 2020 | 1.544B |
| September 30, 2020 | 353.00M |
| June 30, 2020 | -3.346B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.538B |
| December 31, 2019 | 2.689B |
| September 30, 2019 | -1.168B |
| June 30, 2019 | 1.875B |
| March 31, 2019 | 1.968B |
| December 31, 2018 | 3.00M |
| September 30, 2018 | 2.099B |
| June 30, 2018 | 1.819B |
| March 31, 2018 | 1.539B |
| December 31, 2017 | -3.836B |
| September 30, 2017 | 2.712B |
| June 30, 2017 | 3.069B |
| March 31, 2017 | 2.699B |
| December 31, 2016 | 3.099B |
| September 30, 2016 | 3.325B |
| June 30, 2016 | 3.497B |
| March 31, 2016 | 3.567B |
| December 31, 2015 | 4.685B |
| September 30, 2015 | 4.592B |
| June 30, 2015 | 4.497B |
| March 31, 2015 | 4.332B |
| December 31, 2014 | 3.462B |
| September 30, 2014 | 2.724B |
| June 30, 2014 | 3.650B |
| March 31, 2014 | 2.223B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.100B |
| AbbVie, Inc. | 3.604B |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| Amgen, Inc. | 2.375B |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.821B |
| Total Expenses (Quarterly) | 18.32B |
| EPS Diluted (Quarterly) | -8.444 |
| Enterprise Value | 202.61B |
| Gross Profit Margin (Quarterly) | 79.81% |
| Profit Margin (Quarterly) | -134.2% |
| Earnings Yield | -1.81% |
| Operating Earnings Yield | 6.50% |
| Normalized Earnings Yield | 3.238 |